Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMV-MVA Triplex Vaccination of Stem Cell Donors
NCT03560752Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Aug 2018
- Primary completion
- Jan 2022
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of Triplex in cytomegalovirus infection (CMV) (2 arms), sponsored by City of Hope. Primary endpoints: Delayed Engraftment at 1 year, Severe (Grade III-IV) Acute Graft Versus Host Disease at 6 months and 3 more. Started Aug 2018; status: active, not recruiting.
02
Drugs
Triplex
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT03560752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03560752.